Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers

Trial Profile

Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs Atezolizumab (Primary) ; MG1-E6E7 (Primary) ; MG1-E6E7 (Primary) ; MG1-HPV (Primary)
  • Indications Anal cancer; Cervical cancer; Oropharyngeal cancer; Penile cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms Kingfisher
  • Sponsors Turnstone Biologics
  • Most Recent Events

    • 01 Aug 2018 Status changed from planning to recruiting.
    • 23 May 2018 New trial record
    • 16 May 2018 According to a Turnstone Biologics media release, this study is expected to start in Q2 2018. The company has received the US FDA clearance of IND to commence this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top